Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. reports developments for a cardiac and vascular surgery medical device business focused on aortic disease. Recurring updates cover aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, along with preservation services for cardiac and vascular tissues and product sales across international markets.
Company news also includes quarterly and annual financial results, clinical presentations tied to NEXUS and AMDS aortic-disease programs, FDA and PMA-related regulatory developments, financing and capital-structure actions, investor conference participation, and governance matters. The company’s disclosures often connect revenue trends to stent grafts, On-X, BioGlue, preservation services, and other product categories used by cardiac and vascular surgeons.
Artivion (NYSE: AORT) announced the publication of results from the PROACT clinical trial in The Annals of Thoracic Surgery, focusing on the On-X mechanical mitral valve replacement. The trial demonstrated that patients could safely be managed with lower-intensity warfarin and aspirin, enhancing anticoagulation management post-surgery. Presented at the Society of Thoracic Surgeons' Annual Meeting, the findings could influence practice guidelines significantly. Ongoing trials aim to assess the safety of apixaban for patients with On-X aortic valves.